207 related articles for article (PubMed ID: 12216949)
1. Laboratory assays for predicting the severity of haemolytic disease of the fetus and newborn.
Hadley AG
Transpl Immunol; 2002 Aug; 10(2-3):191-8. PubMed ID: 12216949
[TBL] [Abstract][Full Text] [Related]
2. A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn.
Hadley AG
Vox Sang; 1998; 74 Suppl 2():375-83. PubMed ID: 9704470
[TBL] [Abstract][Full Text] [Related]
3. The role of Rh antibodies in haemolytic disease of the newborn.
Hadley AG; Kumpel BM
Baillieres Clin Haematol; 1993 Jun; 6(2):423-44. PubMed ID: 8043933
[TBL] [Abstract][Full Text] [Related]
4. In vitro assays to predict the severity of hemolytic disease of the newborn.
Hadley AG
Transfus Med Rev; 1995 Oct; 9(4):302-13. PubMed ID: 8541713
[No Abstract] [Full Text] [Related]
5. [Positive Coomb's test in newborns; causes and clinical consequences Summary of cases diagnosed in the Blood Bank in the years 2005 to 2012].
Kristinsdottir T; Kjartansson S; Hardardottir H; Jonsson T; Halldorsdottir AM
Laeknabladid; 2016 Jul; 102(7-8):326-31. PubMed ID: 27531851
[TBL] [Abstract][Full Text] [Related]
6. [Management of feto-maternal red cell allo-immunizations].
Bricca P; Guinchard E; Guitton Bliem C
Transfus Clin Biol; 2011 Apr; 18(2):269-76. PubMed ID: 21397546
[TBL] [Abstract][Full Text] [Related]
7. Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn.
Sonneveld ME; Koelewijn J; de Haas M; Admiraal J; Plomp R; Koeleman CA; Hipgrave Ederveen AL; Ligthart P; Wuhrer M; van der Schoot CE; Vidarsson G
Br J Haematol; 2017 Feb; 176(4):651-660. PubMed ID: 27891581
[TBL] [Abstract][Full Text] [Related]
8. Protection against Rh D-haemolytic disease of the newborn by a diminished transport of maternal IgG to the fetus.
Dooren MC; Engelfriet CP
Vox Sang; 1993; 65(1):59-61. PubMed ID: 8362516
[TBL] [Abstract][Full Text] [Related]
9. Serological and immunological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn.
Zupańska B; Brojer E; Richards Y; Lenkiewicz B; Seyfried H; Howell P
Vox Sang; 1989; 56(4):247-53. PubMed ID: 2503936
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn.
Brinc D; Lazarus AH
Hematology Am Soc Hematol Educ Program; 2009; ():185-91. PubMed ID: 20008198
[TBL] [Abstract][Full Text] [Related]
11. [Significance of alloantibodies other than anti-D hemolytic disease of the fetus and newborn (HDF/N)].
Lenkiewicz B; Zupańska B
Ginekol Pol; 2003 Jan; 74(1):48-54. PubMed ID: 12715437
[TBL] [Abstract][Full Text] [Related]
12. What is the best predictor of the severity of ABO-haemolytic disease of the newborn?
Brouwers HA; Overbeeke MA; van Ertbruggen I; Schaasberg W; Alsbach GP; van der Heiden C; van Leeuwen EF; Stoop JW; Engelfriet CP
Lancet; 1988 Sep; 2(8612):641-4. PubMed ID: 2901516
[TBL] [Abstract][Full Text] [Related]
13. Protection against immune haemolytic disease of newborn infants by maternal monocyte-reactive IgG alloantibodies (anti-HLA-DR).
Dooren MC; Kuijpers RW; Joekes EC; Huiskes E; Goldschmeding R; Overbeeke MA; von dem Borne AE; Engelfriet CP; Ouwehand WH
Lancet; 1992 May; 339(8801):1067-70. PubMed ID: 1349101
[TBL] [Abstract][Full Text] [Related]
14. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.
Koelewijn JM; Vrijkotte TG; van der Schoot CE; Bonsel GJ; de Haas M
Transfusion; 2008 May; 48(5):941-52. PubMed ID: 18248570
[TBL] [Abstract][Full Text] [Related]
15. Mononuclear phagocyte assays, autoanalyzer quantitation and IgG subclasses of maternal anti-RhD in the prediction of the severity of haemolytic disease in the fetus before 32 weeks gestation.
Garner SF; Wiener E; Contreras M; Nicolini U; Kochenour N; Letsky E; Rodeck CH
Br J Haematol; 1992 Jan; 80(1):97-101. PubMed ID: 1536816
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the protective effect of maternal FcR-blocking IgG alloantibodies HLA-DR in Rh D-haemolytic disease of the newborn.
Dooren MC; van Kamp IL; Kanhai HH; Gravenhorst JB; von dem Borne AE; Engelfriet CP
Vox Sang; 1993; 65(1):55-8. PubMed ID: 8362515
[TBL] [Abstract][Full Text] [Related]
17. Correlation of serological, quantitative and cell-mediated functional assays of maternal alloantibodies with the severity of haemolytic disease of the newborn.
Hadley AG; Kumpel BM; Leader KA; Poole GD; Fraser ID
Br J Haematol; 1991 Feb; 77(2):221-8. PubMed ID: 2004024
[TBL] [Abstract][Full Text] [Related]
18. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn.
Kapur R; Della Valle L; Sonneveld M; Hipgrave Ederveen A; Visser R; Ligthart P; de Haas M; Wuhrer M; van der Schoot CE; Vidarsson G
Br J Haematol; 2014 Sep; 166(6):936-45. PubMed ID: 24909983
[TBL] [Abstract][Full Text] [Related]
19. [Serological conflict: relation between antibody titer, Liley's zone and the condition of the fetus and newborn infant].
Czeszyńska M; Zieliński M; Czajkowski Z; Hnatyszyn G
Acta Haematol Pol; 1991; 22(2):279-89. PubMed ID: 1841500
[TBL] [Abstract][Full Text] [Related]
20. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
